Apimeds Pharmaceuticals US, Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.6M
- Price
- $4.39
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.75%
- Volume
- 23.4K
About
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Quick stats
Shares outstanding1.5M
Computed float68.5K
Float / shares4.5%
Cash runway (months)-1.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001894525
Websitehttps://www.apimedsus.com
AI Summary
AI-generated1/8
minorbullishproduct launch
NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange
MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US Inc., announced that its NILA token is now available to eligible U.S. users on Webot, a licensed cryptocurrency exchange.
Webot is registered as a Money Services Business with FinCEN and holds licenses in 48 states, allowing access to the token with a minimum entry of $2.
The listing serves as a precursor to the expected October 2026 launch of MindChain, an insured Layer 2 network to which the NILA token will eventually migrate.